Product Pathways - MAPK Signaling
PhosphoPlus® ATF-2 (Thr71) Antibody Duet #8220
|8220S||1 Kit (10 western blots)||---||In Stock||---|
Already purchased this product? Write a Review.
|Duet Includes||Quantity||Applications||Reactivity||Mol. Wt.||Isotype|
|Phospho-ATF-2 (Thr71) (11G2) Rabbit mAb #5112||100 µl||W, F||Human, Mouse, Rat, Monkey||70 kDa||Rabbit IgG|
|ATF-2 (20F1) Rabbit mAb #9226||100 µl||W, IP, IHC-P||Human, Mouse, Rat, Monkey||65 to 75 kDa||Rabbit IgG|
Applications Key: W=Western Blotting, F=Flow Cytometry, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin)
PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.
The transcription factor ATF-2 (also called CRE-BP1) binds to both AP-1 and CRE DNA response elements and is a member of the ATF/CREB family of leucine zipper proteins (1). ATF-2 interacts with a variety of viral oncoproteins and cellular tumor suppressors and is a target of the SAPK/JNK and p38 MAP kinase signaling pathways (2-4). Various forms of cellular stress, including genotoxic agents, inflammatory cytokines, and UV irradiation, stimulate the transcriptional activity of ATF-2. Cellular stress activates ATF-2 by phosphorylation of Thr69 and Thr71 (2-4). Both SAPK and p38 MAPK have been shown to phosphorylate ATF-2 at these sites in vitro and in cells transfected with ATF-2. Mutations of these sites result in the loss of stress-induced transcription by ATF-2 (2-4). In addition, mutations at these sites reduce the ability of E1A and Rb to stimulate gene expression via ATF-2 (2).
For Research Use Only. Not For Use In Diagnostic Procedures.
PhosphoPlus® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Select rabbit monoclonal antibodies are developed, validated, and produced at CST using in part technology under license (granting certain rights including those under U.S. Patents No. 5,675,063 and in some instances 7,429,487) from Epitomics, Inc.